Le Lézard
Classified in: Health, Science and technology
Subjects: Contract/Agreement, Product/Service

Seven and Eight Biopharmaceuticals Inc. Announces Clinical Collaboration

Seven and Eight Biopharmaceuticals Inc. today announced that it has signed a clinical research collaboration agreement with Roche to explore the combination of Seven and Eight's BDB001, an immune modulator targeting toll-like receptors (TLR) 7 and 8, and atezolizumab, a monoclonal antibody against the checkpoint target of PD-L1, in treating solid tumors.

"We are pleased to enter into clinical collaboration with Roche," says Dr. Walter Lau, CEO of Seven and Eight. "Toll-like receptors 7 and 8 are amongst the most promising targets for immuno-oncology, and our dual agonists have demonstrated the ability to stimulate specific types of innate immune responses, generating enhanced adaptive anti-tumor immunity. We hope through our joint efforts with Roche, we can better delineate how to use BDB001 and atezolizumab together in the treatment of cancer patients."

Under the terms of the agreement, Seven and Eight will sponsor and be responsible for the conduct of the clinical study, in which the combined regimen of BDB001 and atezolizumab is studied for safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activities in solid tumor patients.

About Seven and Eight Biopharmaceuticals Inc.

Seven and Eight Biopharmaceuticals Inc. is an Edison, NJ-based, clinical-stage biotech company focused on the development and commercialization of novel immunotherapies for cancer. The company specializes in TLR7/8 programs to treat cancer and has built a comprehensive global intellectual property portfolio in the category of toll-like receptor modulators. Managed by a seasoned team of professionals, the company is progressing a proprietary pipeline of cancer therapeutics, with the lead product BDB001 in Phase I clinical trials in the U.S.

These press releases may also interest you

at 10:38
PharmaCielo Ltd. ("PharmaCielo" or the "Company") , the Canadian parent of Colombia's premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., has been recognized with the prestigious MJ Biz Daily...

at 06:00
For two years, the only hospital in the Middle Florida Keys has been a 1-story temporary facility comprised of modular buildings. Driving into the parking lot would make you think of the temporary buildings you would see at school growing up. The...

at 05:00
In their ongoing efforts to help clients maximize social media and their unique tools, fishbat shares tips for creating Facebook ads for clinical trials. 1. Experiment with different types of content. Facebook ads are common on the platform, but the...

13 déc 2019
Intelligent.com, a trusted resource for online degree rankings and higher education planning, has announced the Top 15 Master's in Child Development Degree Programs for 2020. The comprehensive research guide is based on an assessment of 167...

13 déc 2019
The Government of Alberta announced that it will begin forcibly switching 26,000 patients from their physician-chosen biologic medicines to government-chosen biosimilars beginning July 1st, 2020. These patients include 22,000 Albertans with diabetes,...

13 déc 2019
Schaumburg Dental Studio is hosting an annual toy drive just in time for the holidays. The respected dentists of Schaumburg Dental Studio invite their community to join them in collecting stockings for children in Lake County, IL. The toy drive will...

News published on 19 june 2019 at 20:05 and distributed by: